Cargando…
Sub-acute Toxicity in Non-cancerous Tissue and Immune-Related Adverse Events of a Novel Combination Therapy for Cancer
Brain, lung, and colon tissue experience deleterious immune-related adverse events when immune-oncological agents or radiation are administered. However, there is a paucity of information regarding whether the addition of radiation to immuno-oncological regimens exacerbates the tissue inflammatory r...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6971197/ https://www.ncbi.nlm.nih.gov/pubmed/32010614 http://dx.doi.org/10.3389/fonc.2019.01504 |
_version_ | 1783489672779923456 |
---|---|
author | McKelvey, Kelly J. Hudson, Amanda L. Prasanna Kumar, Ramyashree Eade, Thomas Clarke, Stephen J. Wheeler, Helen R. Diakos, Connie I. Howell, Viive M. |
author_facet | McKelvey, Kelly J. Hudson, Amanda L. Prasanna Kumar, Ramyashree Eade, Thomas Clarke, Stephen J. Wheeler, Helen R. Diakos, Connie I. Howell, Viive M. |
author_sort | McKelvey, Kelly J. |
collection | PubMed |
description | Brain, lung, and colon tissue experience deleterious immune-related adverse events when immune-oncological agents or radiation are administered. However, there is a paucity of information regarding whether the addition of radiation to immuno-oncological regimens exacerbates the tissue inflammatory response. We used a murine model to evaluate sub-acute tissue damage and the systemic immune response in C57Bl/6 mice when administered systemic anti-programmed cell death protein 1 (αPD-1) immunotherapy alone or in combination with stereotactic fractionated 10 gray/5 X-ray radiation to normal brain, lung or colon tissue. The model indicated that combinatorial αPD-1 immunotherapy and radiation may alter normal colon cell proliferation and cerebral blood vasculature, and induce systemic thrombocytopenia, lymphopenia, immune suppression, and altered immune repertoire (including interleukin-1β). Therein our data supports close monitoring of hematological and immune-related adverse events in patients receiving combination therapy. |
format | Online Article Text |
id | pubmed-6971197 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-69711972020-02-01 Sub-acute Toxicity in Non-cancerous Tissue and Immune-Related Adverse Events of a Novel Combination Therapy for Cancer McKelvey, Kelly J. Hudson, Amanda L. Prasanna Kumar, Ramyashree Eade, Thomas Clarke, Stephen J. Wheeler, Helen R. Diakos, Connie I. Howell, Viive M. Front Oncol Oncology Brain, lung, and colon tissue experience deleterious immune-related adverse events when immune-oncological agents or radiation are administered. However, there is a paucity of information regarding whether the addition of radiation to immuno-oncological regimens exacerbates the tissue inflammatory response. We used a murine model to evaluate sub-acute tissue damage and the systemic immune response in C57Bl/6 mice when administered systemic anti-programmed cell death protein 1 (αPD-1) immunotherapy alone or in combination with stereotactic fractionated 10 gray/5 X-ray radiation to normal brain, lung or colon tissue. The model indicated that combinatorial αPD-1 immunotherapy and radiation may alter normal colon cell proliferation and cerebral blood vasculature, and induce systemic thrombocytopenia, lymphopenia, immune suppression, and altered immune repertoire (including interleukin-1β). Therein our data supports close monitoring of hematological and immune-related adverse events in patients receiving combination therapy. Frontiers Media S.A. 2020-01-14 /pmc/articles/PMC6971197/ /pubmed/32010614 http://dx.doi.org/10.3389/fonc.2019.01504 Text en Copyright © 2020 McKelvey, Hudson, Prasanna Kumar, Eade, Clarke, Wheeler, Diakos and Howell. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology McKelvey, Kelly J. Hudson, Amanda L. Prasanna Kumar, Ramyashree Eade, Thomas Clarke, Stephen J. Wheeler, Helen R. Diakos, Connie I. Howell, Viive M. Sub-acute Toxicity in Non-cancerous Tissue and Immune-Related Adverse Events of a Novel Combination Therapy for Cancer |
title | Sub-acute Toxicity in Non-cancerous Tissue and Immune-Related Adverse Events of a Novel Combination Therapy for Cancer |
title_full | Sub-acute Toxicity in Non-cancerous Tissue and Immune-Related Adverse Events of a Novel Combination Therapy for Cancer |
title_fullStr | Sub-acute Toxicity in Non-cancerous Tissue and Immune-Related Adverse Events of a Novel Combination Therapy for Cancer |
title_full_unstemmed | Sub-acute Toxicity in Non-cancerous Tissue and Immune-Related Adverse Events of a Novel Combination Therapy for Cancer |
title_short | Sub-acute Toxicity in Non-cancerous Tissue and Immune-Related Adverse Events of a Novel Combination Therapy for Cancer |
title_sort | sub-acute toxicity in non-cancerous tissue and immune-related adverse events of a novel combination therapy for cancer |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6971197/ https://www.ncbi.nlm.nih.gov/pubmed/32010614 http://dx.doi.org/10.3389/fonc.2019.01504 |
work_keys_str_mv | AT mckelveykellyj subacutetoxicityinnoncanceroustissueandimmunerelatedadverseeventsofanovelcombinationtherapyforcancer AT hudsonamandal subacutetoxicityinnoncanceroustissueandimmunerelatedadverseeventsofanovelcombinationtherapyforcancer AT prasannakumarramyashree subacutetoxicityinnoncanceroustissueandimmunerelatedadverseeventsofanovelcombinationtherapyforcancer AT eadethomas subacutetoxicityinnoncanceroustissueandimmunerelatedadverseeventsofanovelcombinationtherapyforcancer AT clarkestephenj subacutetoxicityinnoncanceroustissueandimmunerelatedadverseeventsofanovelcombinationtherapyforcancer AT wheelerhelenr subacutetoxicityinnoncanceroustissueandimmunerelatedadverseeventsofanovelcombinationtherapyforcancer AT diakosconniei subacutetoxicityinnoncanceroustissueandimmunerelatedadverseeventsofanovelcombinationtherapyforcancer AT howellviivem subacutetoxicityinnoncanceroustissueandimmunerelatedadverseeventsofanovelcombinationtherapyforcancer |